Revolutionizing Cancer Therapeutics: Molecular Pathways and Techniques in Cancer Immunotherapy

Bea Co


Contrary to conventional cancer therapies, immunotherapy manipulates an individual’s body cells to fight cancer, enhancing the active and dynamic immune interactions between the tumour and host. Cancer immunotherapy provides evidence of success through a variety of treatment approaches. Utilizing T-cells and antibodies, immunotherapy strategies such as T-cell engaging bodies, checkpoint inhibitors and engineered T-cells have significantly increased the chance of survival for many cancer patients. The combinations of these immunotherapies have also granted greater success in the elimination of tumour cells. Immunotherapy breakthroughs have the potential to have a lasting impact on cancer treatment. This literature review sheds light on the importance in further research for cancer immunotherapy and a glimpse at all of its powerful results.

Contrairement aux méthodes conventionnelles de traitement anti-cancereux, l’immunothérapie manipule les cellules somatiques d’un patient pour battre contre le cancer, améliorant les interactions immunitaires actives et dynamiques entre la tumeur et l’hôte. Par une variété de méthodes de traitement, il y a une abondance de preuve qui montre le succès exceptionnel dans l’utilisation de l’immunothérapie contre le cancer. Les stratégies immunothérapeutiques, par exemple l’utilisation des anticorps bispécifiques qui engagent les cellules T, des inhibiteurs de checkpoint et les cellules T ingénierées, ont augmenté considérablement la chance de survie pour beaucoup de patients frappés par le cancer. Les combinaisons de ces immunothérapies ont aussi permis des grands succès avec l’élimination des cellules cancéreux. L’immunothérapie a mené à des nombreuses percées qui vont avoir un impact durable sur le traitement de cancer. Elle fournit continuellement des nouvelles découvertes qui ont déjà commencées de révolutionner les thérapies de cancer. Cette revue littéraire éclaircit l’importance de la continuation des recherches concernant l’immunothérapie pout le cancer et donne aussi un aperçu de tous ses résultats puissants. 


Cancer; Immunotherapy; T-Cells

Full Text:



Parish, CR. Cancer Immunotherapy: The Past, the Present and the Future. Immunol. Cell Biol. [online] 2003, 81, 106-113.

Hoption, S.A.; Netten, J.P.; van Netten, C. Dr. William Coley And Tumour Regression: A Place in History or in the Future. Postgrad Med J. [online] 2003, 79, 672-80.

Mellman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age. Nature. [online] 2011, 480, 480–489.

Biemar, F., & Foti, M. Global progress against cancer—challenges and opportunities. Cancer Biology & Medicine. [online] 2013, 10, 183–186.

Yokota, J. Tumor Progression and Metastasis. Carcinogenesis. [online] 2000, 21, 497–503.

Seliger, B. Strategies Of Immune Evasion. BioDrugs. [online] 2005, 19, 347–354.

Rees,R.C. Tumor Immunology and Immunotherapy; Oxford University Press, 2014.

Side effects of chemotherapy. Canadian Cancer Society. en/cancer-information/diagnosis-and- treatment/chemotherapy-and-other-drug- therapies/chemotherapy/side-effects-of- chemotherapy/?region=on (Accessed May 16, 2016).

Janeway, C. Immunobiology: The Immune System in Health and Disease; 6th ed.; Garland Science: New York, 2005.

Understanding Immunotherapy. American Society of Clinical Oncology. http://www.cancer. net/navigating-cancer-care/how-cancer-treated/ immunotherapy-and-vaccines/understanding- immunotherapy (Accessed May 16, 2016).

Remedios, L.V.D. Tumour-Associated Antigens. Clinical Nuclear Medicine. [online] 1980, 5, 82.

The University of Arizona. Introduction to Immunology Tutorial. http://www.biology.arizona. edu/immunology/tutorials/immunology/page3.html (Accessed Aug 11, 2016).

OpenStax. Adaptive Immunity. contents/rshv--bm@3/adaptive-immunity (Accessed Aug 11, 2016).

Klebanoff, C. A.; Gattinoni, L.; Restifo, N. P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunological Reviews. [online] 2006, 1, 214-224.

CAR T-Cell Immunotherapy for ALL. National Cancer Institute. cancer/treatment/research/car-t-cells (Accessed May 16, 2016).

Dimberu, Peniel M., and Ralf M. Leonhardt. Cancer Immunotherapy Takes a Multi-Faceted Approach to Kick the Immune System into Gear. The Yale Journal of Biology and Medicine. [online] 2011, 84, 371–380.

Huehls, A. M., Coupet, T. A., and Sentman, C. L. Bispeci c T-cell engagers for cancer immunotherapy. Immunology and Cell Biology. [online] 2014, 93, 290–296.

Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell, 4th ed.; Garland Science: New York, 2002.

Pardoll, D. M. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer Nat Rev Cancer. [online] 2012, 12, 252–264.

News Releases. Bristol-Myers Squibb Canada. health-canada-approves-yervoy-ipilimumab-for- first-line-treatment-of-adults-with-metastatic- melanoma (Accessed May 16, 2016).

Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J.. Improved Survival With Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine N Engl J Med. [online] 2010, 363, 1290–1290.

Awad, M. M.; Hammerman, P. S. Durable Responses With PD-1 Inhibition In Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. Journal of Clinical Oncology. [online] 2015, 33, 1993–1994.

Brower, V. The CAR T-Cell Race. The Scientist. articleno/42462/title/the-car-t-cell-race (Accessed May 19, 2016).

Wolchok, J. D.; Chan, T. A. Cancer: Antitumour Immunity Gets a Boost. Nature. 2014, 515, 496– 498.

Jarvis, L. Chemical and Engineering News, October 2014, pp 12–19.

Levine, B. L. Performance-Enhancing Drugs: Design and Production of Redirected Chimeric Antigen Receptor (CAR) T Cells. Cancer Gene Therapy Cancer Gene Ther. [online] 2015, 22, 79–84.

Wu, C.-Y.; Roybal, K. T.; Puchner, E. M.; Onuffer, J.; Lim, W. A. Remote Control of Therapeutic T Cells through a Small Molecule-Gated ChimericReceptor. Science. [online] 2015.

Bird, L. Immunotherapy: Remote Control CARs.

Nature Reviews Drug Discovery Nat Rev Drug Discov. [online] 2015, 14, 819–819.

Chemotherapy. National Center for Biotechnology Information. pubmedhealth/pmht0024232. (Accessed May 16, 2016).

A T-Cell Immunotherapy Cure for Cancer | MIT Technology Review. MIT Technology Review. featuredstory/538441/biotechs-coming-cancer- cure (Accessed May 16, 2016).

Themeli, M.; Kloss, C. C.; Ciriello, G.; Fedorov, V. D.; Perna, F.; Gonen, M.; Sadelain, M.. Generation Of Tumor-Targeted Human T Lymphocytes from Induced Pluripotent Stem Cells for Cancer Therapy. Nat Biotechnol Nature Biotechnology. [online] 2013, 31, 928–933.

Topalian, Suzanne L., George J. Weiner, and Drew M. Pardoll. Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology. [online] 2011, 4828– 4836.

Vanneman, M; Dranoff, G. Combining Immunotherapy and Targeted Therapies in Cancer Treatment. Nature Reviews Cancer Nat Rev Cancer. [online] 2012, 12, 237–251.



  • There are currently no refbacks.

Copyright (c) 2017 Journal of Student Science and Technology